Cancer immunology relates to the ability of the immune system to protect a host against tumorigenesis. Understanding how both the innate and adaptive arms of the immune system contribute to immune surveillance and defense has led to the development of several clinically successful anti-cancer therapeutics.
To highlight recent advances in the mechanistic understanding of the immune response to cancer cells and new discoveries that relate to therapeutic interventions, eLife is pleased to present a Special Issue devoted to this exciting topic. This issue presents a collection of highly influential research selected for publication by a specially convened group of experts.
We continue to welcome high-quality research on this topic on an ongoing basis.
Visit our main subject page to explore articles in the wider fields of Cancer Biology and Immunology and Inflammation and sign up to receive the latest research.
Collection
-
Cancer Biology
Long under-appreciated, fibroblast biology is a key aspect of understanding how the immune system responds to tumors and may hold the key to improving immunotherapy in this tricky space.
-
Cancer Biology
-
Physics of Living Systems
A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.
-
Cancer Biology
-
Immunology and Inflammation
HPK1 is an important immuno-oncology drug target that may induce superior anti-tumor immunity through the multiple roles HPK1 may play at multiple steps of the cancer immunity cycle.
-
Cancer Biology
-
Immunology and Inflammation
Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.
-
Cancer Biology
MYC and Twist1 drive metastasis by a novel non-cell-autonomous transcriptional mechanism of eliciting a cytokinome that mediates the crosstalk between cancer cells and macrophages, and its therapeutic blockade inhibits metastasis.
-
Cancer Biology
-
Immunology and Inflammation
Natural IgE supports epithelial cell growth and differentiation in healthy skin, but during chronic tissue inflammation, IgE drives tumour outgrowth of epithelial cells harbouring oncogenic mutations.
-
Cancer Biology
Cancer cell expression of the T-cell co-stimulatory molecule CD80, or treatment with agonistic antibodies targeting the T-cell co-stimulatory receptors OX-40 or 4-1BB, enhances the anti-tumor activity of FAK inhibition.
-
Cancer Biology
-
Immunology and Inflammation
Dissecting structural, cellular and molecular differences between transplanted and spontaneous mouse tumor models, highlighting their relevance for predicting the efficacy of anti-cancer treatments in patients.
-
Cancer Biology
The heterogeneity of immune cell types in glioblastoma tumors depends on the tumor's genetic make-up and treatment status and is an incompletely mined source of novel therapeutic targets.
-
Immunology and Inflammation
Downregulation of mitochondrial activity by immunosuppressive tumor-derived soluble factors leads to systemic unresponsiveness to the PD-1 blockade therapy.
-
-
Cancer Biology
The safety and strong antitumor effects of GPC1-specific CAR-T cells against GPC1-expressing solid tumors were demonstrated by using both syngeneic and xenogeneic mouse models.
-
Immunology and Inflammation
A library of the paired peptide/HLA multimers and artificial APCs allows for construction of a large database of class I-restricted peptides and cognate tumor-reactive TCR genes at an unprecedented scale.
-